期刊文献+

左西孟旦治疗急性心肌梗死并心力衰竭疗效观察 被引量:8

原文传递
导出
摘要 目的观察左西孟旦治疗急性心肌梗死并心力衰竭的有效性及安全性。方法56例急性心肌梗死并发心力衰竭患者,随机分为对照组和左西孟旦组,对照组应用常规抗心衰药物治疗,包括ACEI、利尿剂、洋地黄、扩张血管药物、正性肌力药物:多巴胺、多巴酚丁胺。左西孟旦组采用左西孟旦治疗,使用次数根据症状、心功能的改善、BNP的变化调整。比较两组总有效率、左室射血分数(LVEF)、脑钠肽(BNP)水平变化情况。结果治疗4周后,左西孟旦组总有效率为78.6%,高于对照组的50.0%(x2=4.29,P〈0.05);左西孟旦组LVEF较治疗前提高了10.5%,对照组较治疗前提高了5.9%,两组差异有统计学意义(x2=3.43,P〈0.05);两组治疗后BNP水平均下降,左西孟旦组较对照组下降更明显(t=4.79,P〈0.05)。结论左西孟旦治疗急性心肌梗死并心力衰竭疗效显著,安全性好。
出处 《中国基层医药》 CAS 2012年第6期880-881,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献10

二级参考文献102

  • 1谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-226. 被引量:228
  • 2王小东,李培杰,杨兰,张彤哲,田学林,陈红纲.乌司他丁对心肺复苏后兔心脏保护作用的实验研究[J].中国急救医学,2007,27(5):436-439. 被引量:16
  • 3中华医学会心血管病学分会 中华心血管病杂志编辑委员会.β肾上腺素能受体阻滞剂在心血管疾病应用的专家共识[J].中华心血管病杂志,2009,37:195-209.
  • 4中华医学会心血管病学分会 中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗建议.中华心血管病杂志,2007,35(12):1076-1095.
  • 5Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26: 384-416.
  • 6Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC ( HFA ) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008, 29 : 2388-2442.
  • 7Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure ). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart fa/lure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005, 46: e1-e82.
  • 8Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Aduks: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009, 119: 1977-2016.
  • 9Liang KV, Williams AW, Greene EL, et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med, 2008, 36(1 Suppl) : S75-S88.
  • 10Chen D, Assad-Kottner C, Orrego C, et al. Cytokines and acute heart failure. Crit Care Med, 2008, 36(1 Suppl) : S9-S16.

共引文献910

同被引文献85

  • 1Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of levosimen- dan and its metabolites during and after a 24-hour continuous in fusion in patients with severe heart failure. Int J Clin Pharmaeol Ther,2002,40(10) :465-471.
  • 2Gheorghiade M,Teerlink JR, Mebazaa A. Pharmacology of new a- gents for the acute heart failure syndrome. Am J Cardio1,2005,96 (6) :68-73.
  • 3Ng TM. Levosimendan,a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy ,2004,24 ( 10 ) : 1366-1384.
  • 4Mebazaa A, Erhardt L. Levosimendan : a new dual-action drug in the treatment of acute heart failure. Int J Clin Pract, 2003,57 (5) :410-416.
  • 5Cleland JG, Nikitin N, McGowan J. Levosimendan:first in a new class of inodilator for acute and chronic severe heart failure. Ex-pert Rev Cardiovasc Ther,2004,2( 1 ) :9-19.
  • 6Kaheinen P, Pollesello P, Levijoki J. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmaco1,2004,43 (4) :555-561.
  • 7Paraskevaidis IA, Parissis LIT, Th Kremastinos D. Anti-inflammato- ry and antiapoptotie effects of levosimendan in decompensated heart failure:a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Card- iovase Hematol Agents ,2005,3 ( 3 ) :243-247.
  • 8Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ven- tricular wall stress, and myocardia loxygen uptake. Circulation, 2005,111 (12) : 1504-1509.
  • 9Maytin M, Colucci WS. Cardioprotection:A new paradigm in the management of acute heart failure syndromes. Am J Cardiol, 2005,96 ( Suppl ) : 26 -31.
  • 10Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardio1,2005,99 (3) :409-413.

引证文献8

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部